Industry News

• Abbott completes acquisition of India's Piramal Healthcare Solutions business  Abbott has completed its acquisition of Piramal's Healthcare Solutions business, propelling it to market leadership in the Indian market and further accelerating the company's growth in emerging markets. Abbott expects its pharmaceutical sales in India to exceed $2.5 billion by 2020.
  Abbott September 08, 2010  
• Targeted drug for melanoma shows promise in early clinical testing  The vast majority of patients with advanced melanoma who received an experimental targeted drug called PLX4032 responded to the treatment in a phase I clinical trial, researchers announced last month.
  National Cancer Institute September 07, 2010  
• Bristol-Myers Squibb announces dividend  The Board of Directors of Bristol-Myers Squibb declared a quarterly dividend of 32 cents ($0.32) per share on the $0.10 par value Common Stock of the corporation. The quarterly dividend will be payable on November 1, 2010 to stockholders of record at the close of business on October 1, 2010.
  Bristol-Myers Squibb Company September 07, 2010  
• Oxygen Biotherapeutics TBI Study to be offered to injured Israeli  Oxygen Biotherapeutics announced that Israeli soldiers who suffer severe traumatic brain injury can be enrolled in the company's Phase II-b STOP-TBI trials at clinical sites in Israel. The company expects to reconvene enrollment after the required regulatory adjustments have been approved.
  Oxygen Biotherapeutics, Inc. September 07, 2010  Oxygen Biotherapeutics, Inc.
• PPD Establishes network of sites for conducting phase I trials in patients  PPD announced it has established preferred provider relationships with a network of sites across North America for conducting Phase I trials in patients to meet growing client demand for these services, including Commonwealth Biomedical Research, CNS Network and Lovelace Scientific Resources.
  PPD, Inc. September 07, 2010  
• FDA advisory committee recommends approval of Forest Laboratories' Ceftaroline Fosamil   Forest Laboratories announced the FDA Anti-Infective Drugs Advisory Committee voted 21 - 0 in favor of approval of ceftaroline fosamil for the treatment of community acquired bacterial pneumonia (CABP) and voted 18 - 0in favor of approval for complicated skin and skin structure infections.
  Forest Laboratories, Inc. September 07, 2010  
• Bristol-Myers Squibb to acquire ZymoGenetics for $885 million  Bristol-Myers Squibb and ZymoGenetics announced that the companies have signed an agreement for the acquisition of ZymoGenetics by Bristol-Myers Squibb, for $9.75 per share in cash with an aggregate purchase price of approximately $885 million.
  Bristol-Myers Squibb Company September 07, 2010  
• Bruker introduces Icon, a high-performance desktop MRI system   Bruker Corporation announced the introduction of the Icon(TM), a new easy-to-use 1 Tesla desktop MRI scanner that combines simplicity with compact dimensions, in order to bring preclinical magnetic resonance imaging (MRI) within reach for a broader range of molecular imaging laboratories.
  Bruker Corporation September 07, 2010  
• Medtronic gains CE mark for enhanced CoreValve® delivery catheter system  Medtronic announced CE Mark approval and the first global launch of the Medtronic CoreValve® delivery system with AccuTrak™ Stability Layer for transcatheter aortic valve implantation. AccuTrak’s proprietary technology provides physicians enhanced control in the deployment of the CoreValve device.
  Medtronic, Inc. September 07, 2010  
• Scott Garrett resigns as chairman, president and CEO of Beckman Coulter  Beckman Coulter announced that Scott Garrett has resigned as Chairman, President and CEO, effective immediately. Garrett will continue as a full-time non-executive employee of the company through January 15, 2011, focusing his attention on aiding the Board of Directors during this transition.
  Beckman Coulter, Inc. September 07, 2010  

(previous 10 articles)    (next 10 articles)